ClinicalIntelPulse · Clinical Trial Brief

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief?lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&nct_id=NCT+identifier+%E2%80%94+e.g.+%22NCT04368728%22+%7C+%22NCT05116748%22+%7C+%22NCT04815993%22" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "design": {
    "allocation": "Randomized",
    "arms": [
      "Tiragolumab + Atezolizumab + Carboplatin/Paclitaxel",
      "Placebo + Atezolizumab + Carboplatin/Paclitaxel"
    ],
    "masking": "Double-Blind",
    "primary_purpose": "Treatment",
    "study_type": "INTERVENTIONAL"
  },
  "endpoints": {
    "primary": [
      "Progression-Free Survival (PFS)",
      "Overall Survival (OS)"
    ],
    "secondary": [
      "Objective Response Rate",
      "Duration of Response",
      "Safety/Tolerability"
    ]
  },
  "enrollment": {
    "actual": 534,
    "countries": [
      "United States",
      "Spain",
      "Germany",
      "Japan",
      "Australia"
    ],
    "planned": 534
  },
  "interventions": [
    {
      "name": "Tiragolumab",
      "role": "Anti-TIGIT immune checkpoint inhibitor",
      "type": "DRUG"
    }
  ],
  "outcome_summary": "SKYSCRAPER-01 failed to meet primary PFS endpoint (HR 0.93). Significant negative readout for anti-TIGIT in NSCLC.",
  "query_summary": {
    "nct_id": "NCT04368728",
    "retrieved_from": "ClinicalTrials.gov v2 API"
  },
  "regulatory_implications": "Setback for Roche tiragolumab program. Broader TIGIT class facing headwinds.",
  "trial_identity": {
    "phase": "PHASE3",
    "primary_completion": "2022-12",
    "sponsor": "Hoffmann-La Roche",
    "start_date": "2019-06",
    "status": "COMPLETED",
    "title": "A Study of Tiragolumab in Combination With Atezolizumab and Chemotherapy Versus Placebo in Untreated Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01)"
  }
}